Indivumed Therapeutics

Plan to visit #BioTechX2024 in Basel from October 9-10? Then make sure to join our 𝗽𝗼𝘀𝘁𝗲𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗼𝘂𝗿 𝘁𝗮𝗹𝗸 𝗼𝗻 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟵! Our colleagues, Daniel Beck and Andreas Bolleyer, look forward to meeting you at either one of our presentations and are happy to discuss our data-driven apporach to novel target identification in Oncology with you.  In the meantime, 𝗰𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝗼𝘂𝗿 𝗲𝘅𝗵𝗶𝗯𝗶𝘁𝗶𝗼𝗻 𝘁𝗼𝗽𝗶𝗰𝘀 𝗼𝗻 𝗼𝘂𝗿 𝘄𝗲𝗯𝘀𝗶𝘁𝗲: https://lnkd.in/eugPw_Xi See you next week at BioTechX 2024! #Biotechx24 #multiomics #data #targetidentification #cancerresearch

As we enter October and 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵, we at Indivumed think of those affected by this disease. Our hearts go out to everyone battling breast cancer and their loved ones. 🤍 Our goal is to turn the promise of precision medicine into a reality, offering hope and better outcomes for cancer patients worldwide. Join us this month in raising awareness, supporting those in need, and striving for a future free from breast cancer! #BreastCancerAwarenessMonth #October #BreastCancerResearch #PrecisionMedicine #TeamIndivumed #Hope #Support

⏰ 10 minutes can make all the difference: 𝗢𝘂𝗿 𝗻𝗲𝘄 𝘀𝘁𝘂𝗱𝘆 𝗿𝗲𝘃𝗲𝗮𝗹𝘀 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 𝗶𝗻 𝘁𝘂𝗺𝗼𝗿 𝘀𝗮𝗺𝗽𝗹𝗲𝘀 𝘄𝗶𝘁𝗵𝗶𝗻 𝗺𝗶𝗻𝘂𝘁𝗲𝘀 𝗼𝗳 𝗰𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻, 𝗶𝗺𝗽𝗮𝗰𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗼𝗳 𝗻𝗼𝘃𝗲𝗹 𝗱𝗿𝘂𝗴 𝘁𝗮𝗿𝗴𝗲𝘁𝘀. At Indivumed, we’re committed to collecting the highest quality tumor and normal tissue samples, together with detailed clinical information, to get as close to the molecular reality of cancer as possible and deliver on the promise of precision medicine. Our study, recently published in Cell Death & Disease, analyzed over 1,800 tumor samples across multiple cancer types. We used multi-omics analysis to compare gene expression and protein activity in samples with varying cold ischemia times (the time it takes to preserve surgically removed tissue). The results were striking. We found significant differences in molecular biomarkers such as RNA, proteins and phosphoproteins after just 10 minutes, which became more pronounced the longer the delay before freezing. 𝗢𝘂𝗿 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗽𝗿𝗼𝘃𝗲 𝘁𝗵𝗮𝘁 𝗰𝗼𝗹𝗱 𝗶𝘀𝗰𝗵𝗲𝗺𝗶𝗮 𝘁𝗶𝗺𝗲 𝗵𝗮𝘀 𝗮 𝗺𝗮𝗷𝗼𝗿 𝗶𝗺𝗽𝗮𝗰𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗿𝗲𝗹𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗼𝗳 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗮𝘁𝗮 𝗰𝗼𝗹𝗹𝗲𝗰𝘁𝗲𝗱 𝗳𝗿𝗼𝗺 𝘁𝗶𝘀𝘀𝘂𝗲 𝘀𝗮𝗺𝗽𝗹𝗲𝘀. 𝗜𝗻 𝘁𝘂𝗿𝗻, 𝘁𝗵𝗶𝘀 𝗮𝗳𝗳𝗲𝗰𝘁𝘀 𝘁𝗵𝗲 𝗹𝗶𝗸𝗲𝗹𝗶𝗵𝗼𝗼𝗱 𝗼𝗳 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝗴𝗲𝗻𝘂𝗶𝗻𝗲 𝗻𝗼𝘃𝗲𝗹 𝗱𝗿𝘂𝗴 𝘁𝗮𝗿𝗴𝗲𝘁𝘀 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗿𝗼𝗯𝘂𝘀𝘁𝗻𝗲𝘀𝘀 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀 𝗯𝘂𝗶𝗹𝘁 𝗼𝗻 𝘁𝗵𝗲𝗺. 📖➡ 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝘀𝘁𝘂𝗱𝘆: https://lnkd.in/enVPF-tg Find the press release here: https://lnkd.in/eGvdaZ5Z

Happy European Day of Languages! 🎉 Today we celebrate the 𝗹𝗶𝗻𝗴𝘂𝗶𝘀𝘁𝗶𝗰 𝗱𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗘𝘂𝗿𝗼𝗽𝗲. Did you know that 24 different languages are spoken in the European Union? 🗣️ At Indivumed alone we speak 21 different languages - wow! With colleagues from 18 different nations, we truly are a diverse team. 🌍 How many languages do you speak? Let us know in the comments 👇🏼 #EDL2024 #languages #europe #indivumed

We are thrilled to announce 𝘄𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗷𝗼𝗶𝗻𝗶𝗻𝗴 BioTechX 𝟮𝟬𝟮𝟰! Meet our team from October 9-10 in Basel and discover our data-driven approach to novel target ID in oncology. Can’t wait to see us? Have a look at our 𝗕𝗶𝗼𝗧𝗲𝗰𝗵𝗫 𝗦𝗽𝗲𝗰𝗶𝗮𝗹 𝗪𝗲𝗯𝘀𝗶𝘁𝗲 in the meantime: 💻 https://lnkd.in/eugPw_Xi We look forward to connecting with Pharma partners at our booth #828, come and visit us!  #Biotechx24 #multiomics #data #cancerresearch

🌟 Celebrating Cancer Research Awareness Day 🌟 Today, we team up for cancer research.    At Indivumed Therapeutics, we are committed to advancing precision oncology and deliver on the promise in finding novel targets for innovative drug development.   On this important day, we honor the researchers, clinicians, and especially patients affected, who drive us. Together, we are revolutionizing cancer treatment and improving lives. 💪💙   #CancerResearchAwarenessDay #PrecisionOncology #InnovativeTherapeutics #HighQualityData #DataAnalytics

Recently, we visited our dear partner at the Hospital Universitari Arnau de Vilanova de Lleida and the Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré - IRBLLEIDA in Catalonia, Spain. Not only did we 𝗲𝘅𝘁𝗲𝗻𝗱 𝗼𝘂𝗿 𝗲𝘅𝗶𝘀𝘁𝗶𝗻𝗴 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 by another five years, we also recognized the IRBLleida as a 𝗖𝗲𝗻𝘁𝗲𝗿 𝗼𝗳 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 for their outstanding performance of tissue collection.    IRBLleida has been a key clinical partner of Indivumed since 2019, providing high quality biosamples and detailed patient data to support our identification of novel targets for next generation precision oncology drugs. We are proud and grateful to have this team on our side. Dr. Xavier Matias-Guiu, Principal Investigator for the Indivumed collaboration and Chairman of Pathology at HUAV, said: “Although we have seen great progress in treating cancer in recent years, there is still an urgent need for more effective targeted treatments to control and cure this disease. We are proud to be playing our part in helping Indivumed Therapeutics build the highest quality cancer collection in the world, and excited to see the discoveries that will come from it.” ➡ Want to explore more about the meeting or our Clinical Collaboration? Click here: https://lnkd.in/gjse6m5X #Oncology #ClinicalNetwork #CancerResearch

🚀 We’re #hiring! Join Our Team at Indivumed We have three exciting new positions available! If you are passionate about advancing cancer research and want to be part of a dynamic team, we would love to hear from you. Check out the opportunities below: 1. 🧪 (𝗦𝗲𝗻𝗶𝗼𝗿) 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 𝗔𝘀𝘀𝗮𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 - https://lnkd.in/e7mFUAeC 2. 🧬 (𝗦𝗲𝗻𝗶𝗼𝗿) 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 𝗖𝗲𝗹𝗹 𝗖𝘂𝗹𝘁𝘂𝗿𝗲 - https://lnkd.in/eErirKfX 3. 🔬 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝗔𝘀𝘀𝗶𝘀𝘁𝗮𝗻𝘁 - https://lnkd.in/exwBpxjj Apply now and become a part of our mission! 𝗪𝗲 𝘄𝗮𝗻𝘁 𝘁𝗼 𝗵𝗲𝗹𝗽 𝗯𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗿𝗲𝗰𝗶𝘀𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘁𝗼 𝗰𝗮𝗻𝗰𝗲𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘂𝗹𝘁𝗶𝗺𝗮𝘁𝗲𝗹𝘆 𝗼𝗳𝗳𝗲𝗿 𝗮 𝗰𝘂𝗿𝗲. In case you have questions, feel free to contact Sabine Meinecke, Manager Human Resources Recruiting. #Hiring #JobOpportunity #JoinOurTeam #CancerResearch #Indivumed

🌐 In our current series of introducing our 𝗢𝗻𝗰𝗼 𝗔𝗜-𝗠𝗲𝗱 𝗕𝗼𝗮𝗿𝗱 𝗺𝗲𝗺𝗯𝗲𝗿𝘀, we are happy to present 𝗗𝗿. 𝗦𝘂𝗻 𝗬𝗼𝘂𝗻𝗴 𝗥𝗵𝗮, Professor of Medical Oncology and Director at the Songdang Institute for Cancer Research at the Yonsei University College of Medicince, Seoul, South Korea. When she visited us in December 2023, she pointed out how our process of integrating genomics, transcriptomics, proteomics, and clinical data, can uncover new targets for cancer drugs: "𝗜𝗻𝗱𝗶𝘃𝘂𝗺𝗲𝗱 𝗶𝘀 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝗴𝗲𝘁 𝘁𝗵𝗲 𝘄𝗵𝗼𝗹𝗲 𝗽𝗶𝗰𝘁𝘂𝗿𝗲 𝗼𝗳 𝗮 𝘁𝘂𝗺𝗼𝗿 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗲𝗹𝗹𝘀 𝗶𝗻 𝘁𝗵𝗲 𝘁𝘂𝗺𝗼𝗿 𝗺𝗶𝗰𝗿𝗼𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁. 𝗜𝗻𝗱𝗶𝘃𝘂𝗺𝗲𝗱 𝗮𝗹𝗹𝗼𝘄𝘀 𝘂𝘀 𝘁𝗼 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱 𝘁𝗵𝗲 𝘁𝘂𝗺𝗼𝗿𝘀 𝗶𝗻 𝗱𝗲𝘁𝗮𝗶𝗹, 𝘄𝗵𝗶𝗰𝗵 𝘄𝗶𝗹𝗹 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗯𝗲𝘁𝘁𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝗳𝘂𝘁𝘂𝗿𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀." We deeply value our Onco AI-Med board experts' contributions and are thankful for the collaboration, knowledge sharing, and insights that drive precision oncology forward.   #PrecisionOncology #InternationalCooperation #CancerResearch

Have you joined our poster presentation at #ESMO2024? In this study across various types of cancer, our colleagues, Elisabetta Nale and Julia Bischof, identified the molecular differences between 'hot' and 'cold' tumors, which could help improve immunotherapy treatments. 💡In conclusion, their multi-omic approach revealed the following: 1️⃣ They found known and novel molecular features that discriminate 'hot' and 'cold' tumors pan-cancer 2️⃣ By combining scRNA-Seq from the Broad’s Single Cell Portal with bulk data, our team could differentiate these tumors based on specific immune cell types and their microenvironments 3️⃣ Their findings could play a crucial role in developing precise immunotherapy treatments In case you were not able to attend our poster presentation at ESMO, we have also published the poster online. Make sure to download it below 👇 We look forward to seeing everyone next year in Berlin at ESMO 2025! Download our poster: https://lnkd.in/epHUch85 #esmo2024 #oncology #cancerresearch